Search
Clinician Ordering Portal
Scientific evidence
Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma
Apr 2019
Independent, prospective study with over 3.5 years of follow-up, showing results consistent with previous validation studies with GEP class score as statistically associated with MSS, DMFS and RFS.
Publication: Cancer Medicine
Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions
Apr 2019
Clinical validation study of the 23-GEP in lesions with clinical outcomes and follow-up data.
Publication: Human Pathology
Next-generation sequencing of uveal melanoma for detection of genetic alterations predicting metastasis
Apr 2019
Purpose: To clinically use the UCSF500, a pancancer, next-generation sequencing assay in uveal melanoma (UM) and to correlate results with gene expression profiling (GEP) and predictive factors for metastasis.
Publication: Translational Vision Science & Technology
Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients
Jan 2019
A prospective multicentre cohort study. Multicentre evaluation the early prognostic performance of a genetic signature in a multicentre prospectively evaluated cohort.
Publication: Journal of the European Academy of Dermatology and Venereology
Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck
Jan 2019
Gene expression profile class and node status stratified tumors into significantly different 5-year survival groups by Kaplan-Meier method and both were independent predictors of recurrence in multivariate analysis.
Publication: Head and Neck
Guidance of sentinel lymph node biopsy decisions in patients with T1–T2 melanoma using gene expression profiling
Jan 2019
Multicenter prospective study in T1-T2 tumors showed combining GEP with Breslow thickness and age can provide a more precise determination of SLN positivity risk.
Publication: Future Oncology
Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria
Jan 2019
Discovery of reduced RFS for patients with thin tumors and Class 2B biology and cumulative validation cohort for DecisionDx-Melanoma. DecisionDx-Melanoma was the strongest independent predictor of RFS, DMFS and MSS.
Publication: Journal of the American Academy of Dermatology
Estimation of prognosis in invasive cutaneous melanoma: an independent study of the accuracy of a gene expression profile test
Dec 2018
Independent study of the predictive accuracy of the GEP test, to determine what clinical and histopathologic features predict high-risk classification, and to evaluate how intermediate classes (1B & 2A) performed clinically. Patients with GEP Class 2 result were 22 times more likely to metastasize compared to a Class 1 result.
Publication: Dermatologic Surgery
Management decisions made by physician assistants and nurse practitioners in cutaneous malignant melanoma patients: impact of a 31-gene expression profile test
Nov 2018
Survey to determine the impact of 31-GEP test results on management decisions made by dermatology PA/NPs for cutaneous melanoma patients.
Publication: Journal of Drugs and Dermatology
Cost-effectiveness of a pharmacogenetic test to guide treatment for major depressive disorder
Aug 2018
Gene expression profiling and PRAME status versus tumor-node-metastasis staging for prognostication in uveal melanoma
Aug 2018
To compare the prognostic accuracy of gene expression profiling (GEP) combined with PRAME status versus the clinical Tumor-Node-Metastasis (TNM) staging in patients with uveal melanoma (UM).
Publication: Am J Ophthalmol